Dr. Michael Kelsh joins EpidStrategies, a Division of ToxStrategies LLC
EpidStrategies, a Division of ToxStrategies LLC, is pleased to announce the addition of Dr. Michael Kelsh to our team, adding considerable depth to… read more
Latest News
New Infant RSV Prevention to be Available this Fall
In the United States, a new monoclonal antibody (nirsevimab; trade name: Beyfortus) was recently approved by the FDA and recommended by the CDC… read more
ToxStrategies Acquires Modality Solutions
ToxStrategies LLC is excited to announce that Modality Solutions is joining forces with our firm, greatly expanding our ability to serve the evolving needs of… read more
EpidStrategies scientists present at ICPE 2023, Halifax Nova Scotia, August 23-27
EpidStrategies is excited to be attending and presenting at The International Society for Pharmacoepidemiology’s (ISPE) 39th Annual Meeting (ICPE 2023), August 23rd through… read more
EpidStrategies’ Scientists Support ASPN Award-Winning Abstract
Congratulations to our colleagues at NeuraLace Medical for receiving the Best Abstract Award from the American Society of Pain & Neuroscience (ASPN) 2023… read more
EpidStrategies’ Cara Frankenfeld will be at the American Society for Nutrition’s Annual Meeting, Nutrition 2023, in Boston, July 22-25
Dr. Frankenfeld is an expert in nutritional epidemiology research and has conducted primary data collection research and secondary data analysis using population-based data… read more
EpidStrategies’ Naomi Sacks is at ISPOR
Dr. Sacks is a co-author on four poster presentations at the annual meeting of ISPOR (The Professional Society for Health Economics and Outcomes… read more
Scientists from EpidStrategies are attending ISPOR 2023 in Boston!
Scientists from EpidStrategies are attending ISPOR 2023 in Boston! Please reach out and connect with us and meet the newest addition to our… read more